MX2022007715A - Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. - Google Patents

Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.

Info

Publication number
MX2022007715A
MX2022007715A MX2022007715A MX2022007715A MX2022007715A MX 2022007715 A MX2022007715 A MX 2022007715A MX 2022007715 A MX2022007715 A MX 2022007715A MX 2022007715 A MX2022007715 A MX 2022007715A MX 2022007715 A MX2022007715 A MX 2022007715A
Authority
MX
Mexico
Prior art keywords
gaboxadol
therapeutic treatment
deletion syndrome
deletion
syndrome
Prior art date
Application number
MX2022007715A
Other languages
English (en)
Spanish (es)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2022007715A publication Critical patent/MX2022007715A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
MX2022007715A 2019-12-18 2020-12-18 Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36. MX2022007715A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962949551P 2019-12-18 2019-12-18
PCT/US2020/065801 WO2021127308A1 (en) 2019-12-18 2020-12-18 GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME

Publications (1)

Publication Number Publication Date
MX2022007715A true MX2022007715A (es) 2022-07-19

Family

ID=76439052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007715A MX2022007715A (es) 2019-12-18 2020-12-18 Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.

Country Status (10)

Country Link
US (1) US11364228B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051272A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023507764A (cg-RX-API-DMAC7.html)
KR (1) KR20220114572A (cg-RX-API-DMAC7.html)
CN (1) CN114786669A (cg-RX-API-DMAC7.html)
AU (1) AU2020405060A1 (cg-RX-API-DMAC7.html)
CA (1) CA3164635A1 (cg-RX-API-DMAC7.html)
IL (1) IL293924A (cg-RX-API-DMAC7.html)
MX (1) MX2022007715A (cg-RX-API-DMAC7.html)
WO (1) WO2021127308A1 (cg-RX-API-DMAC7.html)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP1641456B1 (en) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2010015037A1 (en) 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
CN102137667A (zh) 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
AU2015243449A1 (en) * 2014-04-09 2016-09-29 Lineagen, Inc. Genetic markers associated with chromosomal deletion and duplication syndromes
EP3795156A1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Pharmaceutical composition for treating angelman syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CN108024997A (zh) 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions

Also Published As

Publication number Publication date
US20210186938A1 (en) 2021-06-24
JP2023507764A (ja) 2023-02-27
EP4051272A4 (en) 2023-01-04
IL293924A (en) 2022-08-01
CA3164635A1 (en) 2021-06-24
CN114786669A (zh) 2022-07-22
AU2020405060A1 (en) 2022-06-09
WO2021127308A1 (en) 2021-06-24
EP4051272A1 (en) 2022-09-07
US11364228B2 (en) 2022-06-21
KR20220114572A (ko) 2022-08-17

Similar Documents

Publication Publication Date Title
ZA202309638B (en) Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
NZ777871A (en) Small molecule modulators of il-17
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2023010411A (es) Inhibidores de erbb/btk.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MX2019010381A (es) Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
PH12023552741A1 (en) Psilocybin Compositions, Methods Of Making And Methods Of Using The Same
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
PH12021551985A1 (en) Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
JOP20220168A1 (ar) طرق علاج الطحال
PH12022551052A1 (en) Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
AU2017268795A1 (en) Methods of treating behavioral syndromes using pipradrol
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2025014320A (es) Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
WO2020231739A3 (en) Compounds and methods for treating cancer
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.